MARKET

TNYA

TNYA

Tenaya Therapeutics, Inc.
NASDAQ
0.7540
+0.0189
+2.57%
Opening 11:53 07/30 EDT
OPEN
0.7265
PREV CLOSE
0.7351
HIGH
0.7579
LOW
0.7200
VOLUME
1.35M
TURNOVER
--
52 WEEK HIGH
2.350
52 WEEK LOW
0.5316
MARKET CAP
163.62M
P/E (TTM)
-1.6005
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bausch + Lomb Corporation (BLCO) and Curis (CRIS)
TipRanks · 1d ago
Weekly Report: what happened at TNYA last week (0720-0724)?
Weekly Report · 3d ago
Analyst Reaffirms Buy on Tenaya Therapeutics with Unchanged $4 Price Target Amid Advancing Cardio Gene Therapy Pipeline
TipRanks · 07/23 11:27
Weekly Report: what happened at TNYA last week (0713-0717)?
Weekly Report · 07/20 09:09
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Tenaya Therapeutics (TNYA) and Elevance Health (ELV)
TipRanks · 07/16 12:50
Tenaya Therapeutics CFO Eric J. Hyllengren files initial beneficial ownership statement
PUBT · 07/15 01:04
Tenaya Therapeutics grants CFO stock options for 1.65 million shares at $0.84 each
PUBT · 07/15 01:00
Tenaya Therapeutics grants CFO Hyllengren options to buy 1.65 million shares at $0.84 each
PUBT · 07/15 01:00
More
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Webull offers Tenaya Therapeutics Inc stock information, including NASDAQ: TNYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNYA stock methods without spending real money on the virtual paper trading platform.